Hyperbare Zuurstoftherapie: Rapid Assessment - KCE

95 Hyperbaric Oxygenation Therapy KCE Reports 74
74. Mitton C, Hailey D. Hyperbaric oxygen treatment in Alberta. Systematic review. Alberta
Heritage Foundation for Medical Research (AHFMR); 1998. HTA 8 Available from:
http://www.ihe.ca/hta/hta_unit.html
75. Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante. Hyperbaric
oxygen therapy in Quebec. Review. Agence d'Evaluation des Technologies et des Modes
d'Intervention en Sante (AETMIS); 2000. AETMIS 2000-3 RE Available from:
76.
http://www.aetmis.gouv.qc.ca/
Hyperbare Sauerstofftherapie (HBO). 2000.
77. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Hyperbare Sauerstofftherapie
bei der idiopathischen Femurkopfnekrose des Erwachsenen. 2007.
78. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Hyperbare Sauerstofftherapie
bei Brandwunden. 2007.
79. Hailey D, Jacobs P, Perry D, Chuck A, Morrison A, Boudreau R. Adjunctive hyperbaric oxygen
therapy for diabetic foot ulcer: an economic analysis. Systematic review. Canadian Agency for
Drugs and Technologies in Health (CADTH); 2007. Technology Report No 75 Available from:
http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/688
80. Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM, et al. The role of
hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: A double-blind
randomized-controlled trial. European Journal of Vascular and Endovascular Surgery.
2003;25(6):513-8.
81. Guo S, Counte MA, Gillespie KN, Schmitz H. Cost-effectiveness of adjunctive hyperbaric
oxygen in the treatment of diabetic ulcers. International Journal of Technology Assessment in
Health Care. 2003;19(4):731-7.
82. Dempsey J, Hynes N, Smith T, Sproat J. A cost effectiveness analysis of hyperbaric therapy in
osteoradionectosis. The Canadian Journal of Plastic Surgery. 1997;5(4):221-9.
83. Wheen L. The effectiveness and cost of oxygen therapy for diabetic foot wounds. Spums
Journal. 1994;24(4):182-90.
84. Cianci P, Hunt TK. Long-term results of aggressive management of diabetic foot ulcers suggest
significant cost effectiveness. Wound Repair & Regeneration. 1997;5(2):141-6.
85. Boykin JV, Jr., Crossland MC, Cole LM. Wound healing management: enhancing patient
outcomes and reducing costs. Journal of Healthcare Resource Management.15(4):22.
86. Dolezal V. Diabetic foot and hyperbaric oxygen therapy. Prakticky Lekar. 2001;81(3):129-30.
87. Connor H. The economic impact of diabetic foot disease. In: Connor H, Boulton A, Ward J,
editors. The foot in diabetes. Chichester: John Wiley 1987.
88. Marroni A, Oriani G, Wattell F. Cost benefit and cost efficiency evaluation of hyperbaric
oxygen therapy. In: Oriani G, Marroni A, Wattell F, editors. Handbook in Hyperbaric Medicine:
Springer Verlag, New York; 1996. p. 879-86.
89. Marroni A. Cout-efficacité de l'oxygénothérapie hyperbare. In: Wattel F, Mathieu D, editors.
Traité de Médicine Hyperbare. Paris: Ellipses; 2002. p. 589-95.
90. Persels J. Economic aspects of hyperbaric oxygen therapy. In: Kindwall E, editor. Hyperbaric
Medicine Practice. Arizona: Best Publishing Co; 1994. p. 97-118.
91. Rychlik R. Cost-effectiveness: relation of the treatment of diabetic foot lesion with hyperbaric
oxygen therapy versus standard therapy. In: Wattel F, Mathieu D, editors. ECHM Consensus
Conference on Hyperbaric Oxygen in the Treotment of Foot Lesions in Diabetic Patients.
Marly-le-Roi (France): Glaxo Welcome; 1998.
92. Rychlik R, Kilburg A. The basics of health economics: an example from dermatology.
Dermatology Psychosomatics. 2000;1:105-9.
93. Rychlik R, Kilburg A. Sozioökonomische Relevanz der adjuvanten Behandlung des diabetischen
Fußes mit hyperbarem Sauerstoff versus Standardtherapie. Allgemeinarzt (eingereicht).